In: BMC Infectious Diseases, 2015, vol. 15, p. 512
Extended-spectrum β-lactamases producing Escherichia coli (ESBL-E) are increasingly identified in health care facilities. As previously done for the control of methicillin-resistant Staphylococcus aureus, many hospitals have established screening strategies for early identification of patients being carriers of ESBL producers in general and ESBL-E in particular, and have implemented contact...
|
In: Antimicrobial Agents and Chemotherapy, 2016, vol. 60, no. 5, p. 3199–3201
An extended-spectrum β-lactamase (ESBL)-producing and colistin-resistant Klebsiella pneumoniae clinical isolate was recovered from a patient who was treated with cefotaxime. This isolate harbored a blaCTX-M-15 ESBL gene that was associated with an ISEcp1 insertion sequence. Transposition of that tandem occurred within the chromosomal mgrB gene, leading...
|
In: Antimicrobial Agents and Chemotherapy, 2019, vol. 63, no. 1, p. e01809-18
A clinical Pseudomonas aeruginosa isolate resistant to all β-lactams, including ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing from GES-1 by two amino acid substitutions (E104K and G170S). GES-6 possessed an increased hydrolytic activity toward carbapenems and to ceftolozane and a ...
|
In: European Journal of Clinical Microbiology & Infectious Diseases, 2017, p. 1–9
The novel siderophore cephalosporin cefiderocol (S-649266) with potent activity against Gram-negative pathogens was recently developed (Shionogi & Co., Ltd.). Here, we evaluated the activity of this new molecule and comparators against a collection of previously characterized Gram-negative isolates using broth microdilution panels. A total of 753 clinical multidrug-resistant Gram-negative...
|
In: Eurosurveillance, 2017, vol. 22, no. 49, p. 17-00048
OXA-48-like beta-lactamase producing bacteria are now endemic in several European and Mediterranean countries. Among this carbapenemase family, the OXA-48 and OXA-181 variants predominate, whereas other variants such as OXA-204 are rarely reported. Here, we report the molecular epidemiology of a collection of OXA-204- positive enterobacterial isolates (n = 29) recovered in France between...
|
In: European Journal of Clinical Microbiology & Infectious Diseases, 2017, p. 1–5
Multidrug-resistant (MR) Gram-negative (GN) pathogens pose a major and growing threat for healthcare systems, as therapy of infections is often limited due to the lack of available systemic antibiotics. Well-tolerated antiseptics, such as octenidine dihydrochloride (OCT), may be a very useful tool in infection control to reduce the dissemination of MRGN. This study aimed to investigate the...
|
In: Microbiology Spectrum, 2018, vol. 6, no. 4, p. -
Multidrug resistance in Escherichia coli has become a worrying issue that is increasingly observed in human but also in veterinary medicine worldwide. E. coli is intrinsically susceptible to almost all clinically relevant antimicrobial agents, but this bacterial species has a great capacity to accumulate resistance genes, mostly through horizontal gene transfer. The most problematic...
|
In: Journal of Clinical Microbiology, 2014, vol. 52, no. 4, p. 1269–1273
The Carba NP test has been evaluated to detect carbapenemase-producing Pseudomonas spp. directly from blood cultures. This rapid and cost-effective test permits an early identification of carbapenemase-producing Pseudomonas spp. directly from blood cultures with excellent sensitivity and specificity. Results may be useful in particular for guiding the first-line therapy and epidemiological...
|
In: Journal of Clinical Microbiology, 2014, p. JCM.00594–14
Multidrug-resistant Acinetobacter baumannii isolates, and particularly carbapenemase-producing isolates, are increasingly reported worldwide. The biochemically-based Carba NP test, extensively validated for detection of carbapenemase producers among Enterobacteriaceae and Pseudomonas spp., has been modified for the detection of carbapenemase production in Acinetobacter spp. A collection of 151...
|
In: Euro Surveillance, 2013, vol. 18, no. 28, p. 20525
The spread of carbapenemase-producing Enterobacteriaceae (CPE) is a threat to healthcare delivery, although its extent differs substantially from country to country. In February 2013, national experts from 39 European countries were invited to self-assess the current epidemiological situation of CPE in their country. Information about national management of CPE was also reported. The results...
|
